RAE1

Across TCGA pan-cancer cohorts, RAE1 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated RAE1 data layer compared with 24 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher RAE1 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated RAE1 expression acts as an unfavorable survival marker, although some lineages such as LUAD and GBM show a favorable association.

CCRCC, PDAC, and LUAD are the cancer types where RAE1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Tertile	All	0.584	0.902	<.001	68	view →
PDAC	OS	Median	All	0.380	0.585	.013	8	view →
LUAD	OS	Tertile	All	0.999	0.934	.031	4	view →
GBM	DFS	Tertile	All	0.485	0.310	.023	4	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

RAE1–CCRCC (DFS)

Open the CCRCC breakdown →